NDATOPICALTAPE
Approved
Jul 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CORDRAN (flurandrenolide) by Almirall is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1969.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORDRAN (flurandrenolide) is a mid-potency topical corticosteroid indicated for inflammatory and pruritic dermatological conditions. It works by agonizing corticosteroid hormone receptors to reduce inflammation, itching, and skin lesions. The product is formulated as a tape delivery system for sustained local release.
$0.003BPart D
LOE ApproachingDeclining
Mature product with minimal growth trajectory; brand team likely focused on defense and cost management rather than expansion.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CORDRAN currently shows zero linked job openings, reflecting its mature, niche market position and minimal growth investments. Working on this product typically involves maintenance-focused roles in brand management, regulatory compliance, and supply chain optimization rather than innovation-driven positions.
Company
Worked on CORDRAN at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.